Oral Answers to Questions

Jeremy Hunt Excerpts

Tuesday 13th April 2021 Commons Chamber

[Matt Hancock]

I wholeheartedly agree with the hon. Gentleman. I am very proud of how, across this House, people have united to support the vaccination effort and to get those messages out there as he says so clearly. It is very important that we have trusted confidants working in and with communities to explain the benefits of vaccination to those who may be hesitant. For instance, in Leicester we have ensured that within the Somali community, Somali clinicians are administering the vaccine. Having a vaccination centre that is staffed by the Somali community near where they live, even though there is another vaccination centre round the corner, has proved successful in driving up vaccination rates in that community. I pick on that as one excellent example of the national and local systems working together, listening to the data, and working with local communities. and I very much look forward to working with the hon. Gentleman to make that happen.

[Jeremy Hunt (South West Surrey) (Con) [V]]

At the Liaison Committee three weeks ago, the Prime Minister confirmed that there would be a 10-year plan for the social care sector, like that of the NHS, to fix the crisis in social care. Will the Secretary of State tell the House what he thinks that 10-year plan needs to contain, and whether external organisations such as Age UK, the Alzheimer’s Society, Care England, and the Health and Social Care Committee, will be able to contribute to the Government’s thinking on that plan? Will they be able to do so before the plan is published later this year?

[Matt Hancock]

I warmly welcome my right hon. Friend’s enthusiasm and support for that project, which the Prime Minister set out at a high level to the Liaison Committee. We are working hard, including with stakeholders, and the Minister for Care has held a number of roundtables on the subject. We want this to be an open and broad programme, to ensure that we get the right answers to these long-standing questions.

Health and Social Care Update

Jeremy Hunt Excerpts

Thursday 18th March 2021 Commons Chamber

[Matt Hancock]

I welcome the right hon. Gentleman’s support for the vaccines, the vaccine roll-out and the clinically-led approach that we have taken in this country, and I mean that as more than simply a polite gesture. It is vital in this country that we have such a strong cross-party consensus, which includes all parties represented in this House, behind the vaccine programme and behind the science. The science means, of course, that we should and we do publish any side-effects, and we are open and transparent about that, but also that we make an assessment as to the benefits and how those benefits weigh against any side-effects. It is absolutely clear from the data we have seen so far that the vaccines are safe and that they make us safer than not getting vaccinated. That is an absolutely critical fact, and the MHRA will shortly set out more details; it is properly for the independent regulator to set out those details.

The right hon. Gentleman asked about supplies from Moderna. We expect supplies from Moderna in the coming weeks, and I am grateful to Moderna for the work that it has done. Of course, we have always been cautious about setting out future supply details, and the experience of the last 24 hours makes me even clearer that it is far better for us to set out clear commitments to the public in terms of when people can be vaccinated. This means that all over-50s now can come forward and that we are committed to and on target to offer to all over-50s and groups 1 to 9 by 15 April.

However, we know that supply figures move up and down. We have seen that throughout the roll-out, and it is part of the normal management of this roll-out. The commitment I can give the right hon. Gentleman is that, for those who are coming forward for second doses, those appointments will not be delayed because of these supply issues. Also, appointments that are already made will not be cancelled because of supply issues. I therefore say clearly to any member of the public who is watching: the vaccination programme is on track to meet the targets we have set out, and if you get the call from the NHS—whether you get it through a letter, a text, a telephone call or even, these days, an email—take up the offer and get the jab.

The right hon. Gentleman rightly asked about the road map. We are on track for the dates in the road map, and there is no impact on the road map from the changes to vaccine supply that we have been detailing in the last 24 hours.

The right hon. Gentleman asks about the vaccination of children and the autumn vaccination programme. Neither of these is certain. The vaccination of children is currently being assessed in a number of different clinical trials and it is very important that we consider the results of those before making any decision. It is likely that we will need a vaccination booster programme in the autumn, not least to deal with new variants, but that is again not yet certain.

Finally, I am very glad that the right hon. Gentleman welcomed the extra funding that we are putting into the NHS. He asks whether, after six months, there will be more funding if needed for covid purposes. The Chancellor has been absolutely clear from the start of this crisis that the NHS will get what it needs to deal with covid. That is very important, as is the work to restart the NHS in areas where it has had to be paused and, critically, the work that colleagues across the NHS will be doing to recover the backlog of elective work and make sure that everybody can get their appointments and operations in a timely way on the NHS once more. That is the work of the months ahead and I look forward to supporting NHS colleagues in delivering on it.

[Jeremy Hunt (South West Surrey) (Con) [V]]

Was the Health Secretary as concerned as I was by the comments by former Finnish Prime Minister, Alexander Stubb, on the “Today” programme this morning about the threat by the EU Commission President to block exports to countries that were ahead in their vaccination programme? He said that that was a “political reality”, irrespective of any breach of legal contracts that it might involve. Does my right hon. Friend not agree that it is incredibly dangerous to make threats to the supplies of vaccines and components, alongside casting aspersions on their safety at the very moment when vaccines are the only way the world is going to get out of our covid straitjacket?

[Matt Hancock]

I agree with every word that my right hon. Friend said. It is vital that we all work together. The supply chains for the manufacture of these vaccines cross borders. They are often global supply chains and it is vital that we work together to deliver them. There is a need for that co-operation and there is, of course, a need for all countries to respect contract law. That is the basis of international trade, and I am sure that the European Union will live up to the commitments and statements that it has made, including President von der Leyen herself, who has said that there should not be restrictions on companies when they are fulfilling contractual responsibilities. Of course there should not, and we fully expect those contracts to be delivered on, because there are very significant consequences to breaking contract law.

One further point is that the Oxford-AstraZeneca vaccine was developed because of UK taxpayers putting the funding into the science, development and clinical trials and because of AstraZeneca, with an incredibly bold and generous decision, which we fully support—but it was their decision—to offer this vaccine around the world at cost. Working with institutes such as the Serum Institute of India, Oxford and AstraZeneca are providing a vaccine for the whole world. They are not taking a profit from it. We are very proud of that fact, and that makes this materially different from other vaccines that have been developed for commercial advantage. I am not against that at all, but let us celebrate what AstraZeneca has done, and it only underlines how important it is for everybody to work together to keep their populations safe.

Social Care Reform

Jeremy Hunt Excerpts

Thursday 18th March 2021 Westminster Hall

[Jeremy Hunt (South West Surrey) (Con) [V]]

It is a pleasure to serve under your chairmanship, Dr Huq, and to follow such excellent contributions from the hon. Member for Worsley and Eccles South (Barbara Keeley), my hon. Friend the Member for Northampton South (Andrew Lewer) and the hon. Member for West Lancashire (Rosie Cooper). I completely agree with the comment just made by the hon. Member for West Lancashire: it is now or never.

Over the last two decades, we have had 12 White Papers, Green Papers and consultations, and four independent reviews and commissions. I am ashamed to say that a number of them happened when I was Health Secretary for nearly six years, and we were unable to make the progress that I wanted. In the last decade, we have had five Select Committee reports from both the Commons and the Lords.

This time is different, however, because we have just had a pandemic that has shown the whole country how amazing our care staff are and how dependent we are on a group of people who do extraordinary work on very low wages. If we are not going to fix it now, I do not think we ever will. At the same time, the ageing population has continued to age, and last year was the first in human history with more over-65s in the global population than under-fives.

The Health and Social Care Committee undertook a report on this subject last autumn. We are clear that there are three core elements to the reforms. We have to address the catastrophic care costs that see one in 10 people pay more than £100,000 and the terrible dilemma people face of losing their entire life savings to pay for their care home, when they want to leave those savings for their loved ones after they have gone. We should not be forcing people to make those choices in modern Britain.

We have to do more for the workforce, where turnover is about a third. A third of social care staff leave their jobs every year—up to 40% in domiciliary care. Many of them do not get the minimum wage because they are not paid for the time between appointments, yet we know how amazing they are.

We need more funding; we cannot duck that now. The Select Committee thinks a minimum of £7 billion is needed to deal with the catastrophic care issue, the growth in the demography and the minimum wage. We should look at models in Germany and Japan, as my hon. Friend the Member for Northampton South rightly said, when thinking about the best way to fund that.

This is a big ask, but the country was bankrupt after the second world war in 1948 when, with cross-party support, we had the vision to set up the NHS. This is the equivalent challenge for today. It is in tune with the values of the British people. We are a kind country, but our social care system is not kind to the older people who depend on it and get 15-minute slots. It is not kind to the people who work in it.

My message to the Minister is that I know that she cares about this and that behind the scenes she is doing everything that she can, but what is the point of being in Government if not to grasp the nettle on difficult decisions that can transform the lives of ordinary people? Now is the moment to rise to that challenge.

NHS Staff Pay

Jeremy Hunt Excerpts

Monday 8th March 2021 Commons Chamber

[Helen Whately]

My apologies, Mr Speaker.

I do not think that we should play politics with these very serious questions as we come through a pandemic that has hit us and the world so hard, when people have lost their lives, people have lost their jobs, and we as a Government have had to spend so much to support the economy, individuals and, indeed, the NHS. I have been speaking to staff on the frontline of health and social care throughout this pandemic, and I and the Government are grateful to them and thank them from the bottom of our hearts for what they have done and are still doing. While so much of the public sector is having a pay freeze, NHS staff will get a pay rise.

In these difficult times, the Government have submitted their evidence to the pay review bodies and, as I said in my opening statement, they will report back to us. They will look at a wide range of evidence, including, for instance, evidence from trade unions, inflation, and the wider situation with the economy and pay levels, and we will of course look at their recommendations carefully.

The right hon. Gentleman talked about the vote that we had on the NHS Funding Act and, yes, we absolutely did vote for it. We are fulfilling our commitment to record investment in the NHS—£34 billion more. He also referred to the long-term plan and, although not something we voted on, the 2.1% increase within it will be invested in the NHS workforce this year. That will include not only these pay rises, but pay progression and further investment in the NHS workforce.

We will continue to invest in more doctors and more nurses for the NHS, and I wish that the right hon. Gentleman would welcome that. We will continue to support the recovery of our economy and restore our public finances, so that we can fund our NHS not just through the pandemic, but into the future.

[Jeremy Hunt (South West Surrey) (Con) [V]]

The long-term plan budgeted for a 2.1% increase in salaries, which has now gone down to 1%, but an even bigger gap in last week’s Budget was identified by the Office for Budget Responsibility as a lack of funding from next year for annual covid vaccinations, for Test and Trace, for long covid and for millions of catch-up operations delayed by the pandemic. What discussions has the Health Secretary had with the Chancellor about that gap in funding, and where will that money come from?

[Helen Whately]

I thank my right hon. Friend for his question. He mentions the 2.1% increase within the long-term plan. That figure covers not only this pay rise for the NHS workforce, but the pay deals that have been agreed for staff in other multi-year pay deals, pay progression, and other investment in the workforce. As for his question on funding for the broader extra covid costs, that is not in the main NHS budget. Just as we had £63 billion invested in those costs throughout this year, there is an extra £22 billion set aside for covid costs outside the NHS budget and also £3 billion specifically for recovery and bringing down waiting lists.

Covid-19 Update

Jeremy Hunt Excerpts

Tuesday 2nd March 2021 Commons Chamber

[Matt Hancock]

The right hon. Gentleman says he likes it. We always knew that he was misplaced over there. His problem is that sometimes his rhetoric is aimed more at his Back Benchers than what he thinks is right. I urge him to listen to his conscience and to back us and the businesses that are making this vaccination roll-out happen, and to put that support into practice.

The right hon. Gentleman asked about sequencing—again, done by a brilliant combination of academics, Government and private businesses. We are now sequencing a third of the positive tests in this country. That is not yet a full survey of all the positives, although we are working towards that, but it does mean that we are able to spot the variants much more than anywhere else in the world. We currently provide around 40% of the total global sequences of this disease—this virus—and we are driving up that sequencing capacity.

The right hon. Gentleman asked about increasing the uptake of vaccination. He was quite right to, and we are working with faith groups and local directors of public health and others. Councils have a very important role to play alongside pharmacists and, of course, GPs in increasing the vaccination uptake. However, the vaccination uptake has been very, very high—higher than I expected—and I am really thrilled about that.

Finally, the right hon. Gentleman asked about making sure that the road map follows data, not dates. We have rigorously set out the gap between the steps to ensure that we can see the effect of one step before we take the other. That is with the goal of having this road map as a one-way route out of restrictions so that we can all get back to the freedom that we crave.

[Jeremy Hunt (South West Surrey) (Con) [V]]

I congratulate the Health Secretary on the brilliant progress of the vaccine roll-out, which is a personal achievement for him as well as a collective achievement for the Government. I also thank him for transparency in that programme and the transparency on the risks of the new Brazilian variant.

I would like to ask about transparency in another area, which is the new integrated care systems that he is planning in his White Paper and the concerns expressed by the Nuffield Trust, the King’s Fund, the Health Foundation and NHS providers at this morning’s Health and Social Care Committee about the lack of detail on how the public will know how well their local ICS is doing. Sir Robert Francis told the Committee that he favoured asking the CQC to Ofsted-rate the new ICSs and I wonder whether my right hon. Friend thinks that that might be a solution to the accountability issue.

[Matt Hancock]

Transparency has played a vital role in our approach to responding to this virus, and I think that is an important lesson from it that should be heeded globally. In terms of the future of the NHS arranged around the ICSs, that transparency will be important, too. There will be a crucial role for the Care Quality Commission, which currently rates hospitals according to, as my right hon. Friend put it, an Ofsted-style rating. It is vital that the CQC has a similar role when it comes to ICSs, and I look forward to working with him and other members of his Committee to make sure that we get the details of that right.

Oral Answers to Questions

Jeremy Hunt Excerpts

Tuesday 23rd February 2021 Commons Chamber

[Matt Hancock]

The hon. Lady is a long-standing and passionate campaigner for Kuvan, and I pay tribute to the work that she has done. The NICE methods review looks at the question she raises. It is important that we have a clinically-led process for approval of medicines, and I know she agrees with that. The question is ensuring that the details live up to that principle. The methods review will make sure that we take advantage of advances in medical technology, which will, I hope, allow us to bring drugs and treatments to patients of rare diseases who need them more quickly than in the past.

[Jeremy Hunt (South West Surrey) (Con) [V]]

Can I add my support to the previous question about the urgent need to sort out the issue of Kuvan, because I too have constituents suffering very badly from the long wait that they have had?

I wanted to talk to the Secretary of State about support for NHS frontline staff, who have done such a magnificent job this year but worry that, even now, we are not training enough doctors and nurses for the long-term needs of the NHS, and that is the crucial way that we will reduce the pressure on them. So could I ask him: will he be publishing a workforce plan this year, will that have independent projections as to the number of doctors and nurses the NHS will need in every specialty over the next couple of decades and will he commit to funding the number of training places that we need to make sure that we meet those needs of the future?

[Matt Hancock]

The good news is that, thanks in part to the work that my right hon. Friend did when he was in my shoes, we now have a record number of doctors in the NHS and he will have been as pleased as I was to see the record number of applicants to nursing places as well, because we need both more doctors and more nurses. I am delighted that, during the pandemic, we have increased numbers very substantially. On nurses, we are on track to meet our manifesto commitment to 50,000 more nurses, and we have seen a significant increase—just under 10,000—in the number of doctors too, so there is significant progress. Of course there is more to be done, and of course we will need to set out the route to that, as he suggests. The time is not quite right now, because right now there are still very urgent needs and pressures, thanks to the pandemic—I am sure that he and the Select Committee understand that—but this is undoubtedly a question that we will return to.

Future of Health and Care

Jeremy Hunt Excerpts

Thursday 11th February 2021 Commons Chamber

[Matt Hancock]

I will take that as cautious support. I know that the hon. Gentleman sometimes has to say these things, but I am very glad that he leaves the door open for yet more enthusiastic support in the future, not least because of all the questions that he just asked. The proposals on the table—the proposals in the White Paper—are addressed directly to make the improvements that he calls for.

The hon. Gentleman raised an important point about the vaccination programme. The vaccination programme is one of the largest and also one of the most successful civilian operations that has happened in this country, and that is because of the teamwork among the NHS, local authorities, the Department and the brilliant civil servants who work in the vaccine taskforce. It is that combination, that teamwork and that integration which is making the programme the great success that it is.

The hon. Gentleman asked about timing, and I say to him: why argue for delay? Why stop work to integrate? Why stop work to ensure the NHS is more accountable? When people are working so hard in the NHS for us, why should we not work hard in this Parliament to give them the legislative support that they need and have asked for? That is the question he needs to answer if he wants to continue an argument for delay. If not now, when? There is no better time than immediately, so I hope that he will, on reflection and on reading the White Paper, come forward with enthusiastic support.

I absolutely look forward to debates about the details and the implementation. I look forward to the parliamentary passage of a significant piece of legislation in the future, and I look forward to the hon. Gentleman’s engagement on that, but the removal of bureaucratic barriers cannot wait. The increase in the integration of the system should not have to wait, and accountability for this enormous amount of taxpayers’ money to this House, and through this House to the citizens whom we serve, is something that should be welcomed right across this Parliament, and I hope that it will be.

[Jeremy Hunt (South West Surrey) (Con) [V]]

May I start my comments by thanking the brilliant staff at the Royal Surrey County Hospital for the wonderful care they gave me—this morning, as it happens, when I unfortunately slipped over and broke my arm on a morning run. I have just come from the hospital.

It is a very big deal to do a structural reorganisation of the NHS, and I know from my time as Health Secretary how distracting it can be, but it is none the less the right thing to do and a brave thing to do, because NHS staff want nothing more than to be able to give joined-up care—joined up between hospitals, GP surgeries, the social care system and community care—and the current structures make that more difficult than it should be.

I also welcome the public health measures, particularly on obesity, given the high mortality rates that obese people have had during the pandemic. However, these integrated care systems are going to be very powerful, so my question to the Health Secretary is this: how will the public know in their area about the quality and safety of care, and whether waiting lists are being properly managed? How will they know how good all that is? Is he planning to ask the CQC to do Ofsted ratings, as it successfully does for hospitals and GP surgeries?

[Matt Hancock]

I pay tribute to my predecessor’s work setting up integrated care systems in the first place. In a way, this legislation builds on the foundations that he laid when he was in my job, and I look forward to working with the Health and Social Care Committee on the legislation as it proceeds. We have already had discussions, and I am grateful for the Select Committee’s work so far and the insights it has provided.

The question my right hon. Friend raises about the accountability of ICSs is absolutely central, not just to accountability for the use of taxpayers’ money, but to driving up both the quality of care for patients and the health of the population the ICSs serve. It is critical that we ensure the correct combination of high levels of transparency, the role of the CQC as inspector, and accountability up from the ICS, through NHS England, to Ministers and therefore Parliament, and through our democratic processes to taxpayers. The White Paper sets out at high levels how that accountability will work. The details will be a matter for the Bill. The combination of transparency and clear lines of accountability are vital to make sure that while we use the integration provided for in the Bill to empower frontline staff to deliver care better, they are held to account for the delivery of that care and, critically, the outcomes for the population as a whole whom we serve.

Covid-19 Update

Jeremy Hunt Excerpts

Tuesday 9th February 2021 Commons Chamber

[Matt Hancock]

I was listening very carefully to the hon. Gentleman, and I think I take that as support for the measures we are bringing in.

On the specific points the hon. Gentleman raises, he is absolutely right that further driving up vaccination rates is critical. I am delighted by the vaccination rates and the uptake of over 90% in all of the groups over the age of 75, and rapidly rising now—above 75% and rising fast—in the 70 to 74s. I agree with him very strongly on the need to keep driving up the uptake of the vaccine. The Minister for Covid Vaccine Deployment, my hon. Friend the Member for Stratford-on-Avon (Nadhim Zahawi), is leading the efforts across the NHS and local authorities to try to make sure that we can increase vaccination rates further. Nevertheless, the take-up has been absolutely superb so far, and there is still more to do.

I will absolutely look into the points the hon. Gentleman made about Leicester. I know that it is close to his heart and a very important matter.

I will commit to the hon. Gentleman to keep the red list up to date. It is important that we take the measures that are necessary to protect this country. There are countries around the world on a so-called green list that have very low rates of infection and no known variants of concern. I am absolutely in favour of keeping the red list up to date, but I also think it is important that we are proportionate when there are countries that do not have a record of variants of concern. However, we will use the fact that we will sequence every positive test from somebody who comes through the border as a global system of vigilance to make sure that we are always looking for those variants of concern.

The hon. Gentleman raised the issue of financial support. I reiterate that the £500 support is available for anybody on low incomes, so people should come forward for testing in all circumstances. I am absolutely delighted at the level of testing as well. There is now an average of over 650,000 tests a day done in this country, which is obviously a very substantial number.

The hon. Gentleman raised the point about air filtration systems, which are important. I will point him to guidance from the Business Department on air filtration systems and on PPE—we have taken clinical advice and follow the clinical advice on the correct levels of PPE.

Finally, I know that the issue of children of alcoholics is very close to the hon. Gentleman’s heart and to those of many colleagues across the House, so I will absolutely look at how we can ensure that the extra funding we have provided in this space continues to support the vital work not just of those in the NHS, but especially of charities that do so much in this space. The invitation to run the marathon with him is a very interesting one. I am not sure I have enough time for training this year, but it is certainly something I would like to do at some point in the future.

[Jeremy Hunt (South West Surrey) (Con) [V]]

I strongly support the new measures. The higher the number of new daily cases, the more opportunities for variants and mutations to emerge, including ultimately some that may be immune to the vaccine. So does the Health Secretary agree that the central priority now must be to bring down the number of new daily cases, and as we do that, is he planning to introduce enhanced contact tracing for all new cases, including Japanese-style backward contact tracing and genomic sequencing of every new case?

[Matt Hancock]

We have the biggest genomic capacity in the world by some margin, and when the number of cases comes down, as our genomic capacity continues to expand—we plan to more than double it in the coming months—I hope to get to the position where we can genomically sequence every positive case, yes, but we are not there yet.

The strategy that I outlined to tackle new variants, of which the border measures are an important part, is itself one part of the four conditions that the Prime Minister set out for when we can lift measures. The other three are the successful roll-out of the vaccine, which is going very well, and the fall in the number of hospitalisations and the fall in the number of deaths, both of which, as I said, are moving in the right direction but are still too high. Therefore, this strategy to tackle new variants is crucial. The number of cases is a factor, because that itself determines the number of new variants. The conclusion of all that is that we must all stick to the rules now, and the more we stick to the rules now, the sooner we can get out of this.

Covid-19 Vaccine Update

Jeremy Hunt Excerpts

Thursday 4th February 2021 Commons Chamber

[Nadhim Zahawi]

I am grateful to the hon. Gentleman for his constructive way of engaging with the vaccination deployment programme. On trials, we have two running currently, both with Public Health England. The Vivaldi trial is testing residents of care homes, who were in category 1 of the JCVI categories. The second is Siren, which is testing frontline health workers, who are in category 2. As Jonathan Van-Tam, the deputy chief medical officer, has said, we will know the infection and transmission data from those trials in the next few weeks. Of course, the Oxford data is very promising—it needs to be peer reviewed—but those trials will also capture the Oxford vaccine, because obviously that came on site in January.

On the priority list, the JCVI looked very closely at both black, Asian and minority ethnic and, of course, other considerations, including by profession, and came down clearly on the side of age as the deciding factor in people’s risk of dying from covid. This is a race against death, hence the nine categories, which we are going through, and we will continue to do so. A number of professions will be captured in those categories. Of course, those with extremely severe illness will be captured in the category for the severely extremely vulnerable, and others will be captured in further categories down the phase 1 list.

I certainly think it would be wrong to change the JCVI recommendation, because categories 1 to 9 account for 99% of mortality. When we get into phase 2, we would welcome a debate and, of course, will ask the JCVI about including professions such as teachers, shop workers and police officers, who through their work come into contact with much greater volumes of the virus than others do, and it will advise us accordingly.

On BAME and ethnicity, the NHS now collects such data, and we are publishing it. We are doing an enormous amount of work not only across Government, but with the NHS, to ensure that we bring in local government so that we can begin to share data. I would welcome us working much closer with local government and the NHS so that we can identify, to the individual level, the people we need to protect as soon as possible.

I put it on the record that I want clinical commissioning groups to share data with MPs. Several colleagues—[Interruption.] Including you, Madam Deputy Speaker; I can see you nodding away vigorously. CCGs should and must engage with local politicians, because MPs get a lot of emails and telephone calls from concerned constituents in the top four most vulnerable categories. Of course, the NHS has plans to publish CCG-level data very soon.

As for care home staff, we had a fantastic response through the care home vaccination programme, which is category 1, and we continue to do more with staff to encourage them to be vaccinated, because we make four visits into care homes. Visit one is for the first dose, visit two is to try to vaccinate those who may have been infected the first time, because people cannot be vaccinated until after 28 days, visit three will be for second doses, and so on. We are getting greater traction with care home staff, but the hon. Gentleman is right to mention that. There is a big focus on helping them to go to hospital hubs and, of course, their primary care networks.

On the second dose, everyone who has had a first dose of Pfizer will get a second dose of Pfizer within that 12-week dosing period. That will begin in March in the usual way that the NHS does vaccinations. Everyone who has had a first dose of Oxford-AstraZeneca will get a second dose of Oxford-AstraZeneca within 12 weeks as well.

The hg is right to ask about people wanting the option of going either to a national vaccination centre or to the PCN. If right hon. and hon. Members have particular cases, please point them to us and we will do everything we can to ensure that that is facilitated.

The hon. Gentleman rightly highlighted HIV clinics. I will take that matter away and see whether there is a workaround for those who want to have that information remain private from their GP. We will see what we can do.

This is World Cancer Day, and there is now real excitement in the scientific community in the UK about the messenger RNA vaccine, because people can begin to think about vaccines for cancers as well. However, the hon. Gentleman raises an important point about those who care for the clinically extremely vulnerable, and we want to ensure that we deliver the JCVI phase 1 and then very quickly reach the rest of the population.

[Jeremy Hunt (South West Surrey) (Con) [V]]

I congratulate the Minister on his leadership of the vaccine roll-out programme, which really is one of the most impressive anywhere in the world. Indeed, I also commend the Health Secretary for the foundations that he laid last year.

Now that we know that mutations and variants are the name of the game, I want to ask the Minister about a worst-case scenario: a variant that is wholly immune to the vaccines that we are currently distributing. How possible is it that we could see that in the next few months in the UK? Has the Manaus variant, which people are particularly worried about, arrived here from Brazil? If we did see such a variant, what is the timescale not just to develop a new vaccine that works against it, but to manufacture it and get it approved by regulators so that it is ready to go?

[Nadhim Zahawi]

I am grateful to the Chair of the Health and Social Care Committee for his question, and he is absolutely right. The manufacturers are already working on variants to their vaccine to take into account the mutation of the virus. Viruses will mutate to survive and this virus is no different. There are about 4,000 mutations now around the world, some more concerning than others. We have, in the United Kingdom, a genome sequencing industry that is a world leader—about 50%, or just under, of the sequencing has taken place in the United Kingdom. Not only are we working with the current manufacturers—Pfizer-BioNTech, AstraZeneca and Moderna —that have been approved, but we are also looking at how we can make sure that we make the most of the new messenger RNA technology, which allows the rapid development of vaccine variants that will then deal with the virus variants as rapidly as possible. When I spoke to the Science and Technology Committee a few weeks ago, I said that we were planning to have in place the ability to go from the moment that we can sequence a variant that we are really concerned about to the moment that we can have a vaccine ready in between 30 to 40 days, with then, of course, the manufacturing time.

We have invested in Oxfordshire, in the Vaccines Manufacturing and Innovation Centre, and in the Cell and Gene Therapy Catapult Manufacturing Innovation Centre in Braintree—£127 million there and just shy of £100 million in Oxfordshire—to be ready to manufacture any vaccine that we would need. The Prime Minister, of course, also visited those making what I refer to as our seventh vaccine, the Valneva vaccine. That is a whole inactivated virus, so it does not just work on the spikes in the way that the two current vaccines that we are deploying work. It works on the whole of the virus, which is much more likely to capture any mutations from the spikes and therefore be incredibly effective. We have invested in that production facility in Scotland so that we can have that vaccine as a future-proofing of annual vaccination strategies or a booster in the autumn, if necessary.

Covid-19 Update

Jeremy Hunt Excerpts

Tuesday 2nd February 2021 Commons Chamber

[Matt Hancock]

To answer the hon. Gentleman’s many questions, he is absolutely right to raise the importance of coming down hard on the cases of new variants that we have discovered here in the UK. These are cases that have been seen over the past two months. The action that we are putting into place is to make sure that we stop further spread, and further spread in the community, alongside the action taken to ensure that there is no spread from those who have a history of international travel. As he knows, we have brought in tougher action at the border and we stand ready to do more.

The hon. Gentleman asks for the SAGE minutes to be published. They are published regularly. He also asks about the neighbouring postcodes to those where a new variant case has been found, where it is a new variant of concern. We absolutely do that where it is epidemiologically sensible. For instance, if the case is found on the border of a postcode, obviously we go across that border. We also investigate linked premises—for instance, if somebody had a child at a school or is going to work in a particular workplace—and, working with the director of public health, we will ensure that testing is directed there as well.

The hon. Gentleman raises the issue of isolation payments. We have the £500 isolation payment in place, so nobody should, as he put it, go hungry because they have to isolate. What is critical in these areas is that people stay at home unless they absolutely have to go out. It is imperative that people follow the rules to get these new variants completely under control.

He asks about the care home success. I am delighted that we have been able to reach so many care homes. I said in my statement that we have reached 10,307 care homes in England. There are 110 care homes where the vaccination programme is still outstanding because they have had outbreaks and, for clinical reasons, the vaccination programme cannot start there, but it will as soon as it is clinically possible.

The hon. Gentleman also asks about the data being shared from the vaccination programme. That data is now routinely shared with local directors of public health, precisely for the reasons that he set out—so we can reach more parts.

Finally, he ends on the question of education. Of course we understand how challenging the impact of this lockdown is on those with children who have to be schooled at home. That is why the Prime Minister said that schools should be the first thing to open when it is safe and possible to do so. Sadly, that time is not yet, but the more that we all follow the rules that we have set out so clearly, the quicker that time will come.

[Jeremy Hunt (South West Surrey) (Con) [V]]

I thank the Health Secretary for liaising with me on the issues in Surrey over the weekend, where the actions taken by him and the outstanding leader of Surrey County Council, Tim Oliver, are absolutely right. My right hon. Friend mentioned that, at the weekend, we reached the milestone of offering the vaccine to everyone in care homes, except for where there has been an outbreak. Does he agree that we should crown that tremendous achievement by making 2021 a year as significant for the social care sector as 1948 was for the NHS—the year it was founded—with a long-term financial settlement implementing Dilnot and setting it up for the future with a 10-year plan?

[Matt Hancock]

My right hon. Friend knows that we set out in our manifesto, committed in the manifesto and were elected on a manifesto to resolve the long-standing problems in social care. The Prime Minister has set out to the Liaison Committee, of which my right hon. Friend is a member, the timetable on which he hopes that we are able to deliver that commitment. Alongside dealing with this pandemic, we are working to deliver our manifesto commitments, whether on social care or the 40 new hospitals or the 50,000 more nurses. I look forward to being held to account by the Select Committee on Health and Social Care on those commitments.